rs137852593
|
|
|
0.740 |
GeneticVariation |
BEFREE |
The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients.
|
11103816 |
2000 |
rs137852593
|
|
|
0.740 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852581
|
|
|
0.720 |
GeneticVariation |
BEFREE |
T can nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer mutation.
|
17591767 |
2007 |
rs137852581
|
|
|
0.720 |
GeneticVariation |
BEFREE |
SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant.
|
9092797 |
1997 |
rs137852581
|
|
|
0.720 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852571
|
|
|
0.710 |
GeneticVariation |
BEFREE |
In prostate cancer DU-145 cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced AR activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.
|
12507906 |
2003 |
rs137852571
|
|
|
0.710 |
GeneticVariation |
UNIPROT |
|
|
|
rs1340026226
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852567
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852580
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852582
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852583
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852584
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852591
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs138454018
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs78686797
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs868669253
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |
rs1034866440
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer.
|
11847524 |
2002 |
rs137852569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer.
|
12210487 |
2002 |